mesothelin-based CAR T cells targeting MUC16 / Weill Cornell Medicine - LARVOL DELTA

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models. (PubMed, J Exp Med) - "Intravesical adoptive transfer uncouples local antitumor efficacy from potential systemic toxicity-a feature conserved across several T cell immunotherapies with on-target off-tumor activity. Collectively, these findings substantiate MUC16 as a therapeutic candidate and validate intravesical delivery as a platform for T cell immunotherapies in the management of organ-confined BCa."

IO biomarker • Journal • Preclinical • Bladder Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • MSLN • MUC16